# Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

> **NCT00777179** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 117 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Vandetanib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00777179
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-01
- **Final completion:** 2011-12
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2016-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00777179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00777179, "Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00777179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*